Refine by
Protein Therapeutic Articles & Analysis: Older
43 news found
Its end-to-end rare disease therapy development solutions cover a full package of therapeutic development services, which include small molecule, cell therapy, gene therapy, therapeutic antibody, therapeutic peptide, and therapeutic protein. ...
Introduction We recently sat down with one of our valued customers, Dr Alexis Rossignol (Clean Cells), to discuss his experience with VIPS PRO, our cutting-edge technology designed to streamline and enhance the early stages of cell line development. This interview provides insight into Clean Cells’ quest to automate and increase single-cell seeding while having undisputable proof ...
This cutting-edge Succinimidyl Carboxymethyl Ester branched 2ARM PEG offers a revolutionary approach to amine PEGylation, enhancing the modification of proteins and other biologics. PEGylation, the technique of attaching a PEG derivative to molecules, is crucial for improving the water solubility and biocompatibility of protein drugs. The Y-Shape PEG NHS ester ...
The company's portfolio includes immune checkpoint proteins, CAR-T cell targets, CD antigens, fluorescent-labeled recombinant proteins, PROTAC targets, and more. ...
Delivery of LNP-formulated mRNA for transient and local translation of therapeutic proteins offers a unique opportunity to encode for multiple therapeutically active components in a single treatment. ...
ByeTheRNA
This platform uses an innovative vector approach to pack split genes into individual vgAAV vectors and generate a full-length protein via mRNA trans-splicing. ViGeneron is a spin-off of the Ludwig-Maximilians-University (LMU) in Munich. ...
This is a crucial quality attribute of therapeutic protein drugs. Therefore, accurate characterization of glycosylation in biopharmaceutical processes requires the use of quantitative analytical methods. Given the significance of glycosylation in protein drugs, CD BioGlyco offers clients thorough services for characterization of glycosylation ...
Juvena Therapeutics, Inc. (“Juvena”), a biotechnology company scaling a computational platform to map the therapeutic potential of secreted proteins, announced today that it has raised $41 million in an oversubscribed Series A, bringing its total funding to $50 million. ...
Lumen Bioscience pioneered genetic engineering methods to highly express bioactive proteins in spirulina. The published research details how this platform was used to express a malaria protein antigen that can be delivered intranasally and later boosted with a simple oral booster. ...
At Cyrus, we see the AIFolds, together with protein design AI and physics-based traditional models, as the foundation models of protein engineering and design, leading to a next generation of new biologics derived either from natural proteins or fully designed from scratch. ...
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the company’s chief executive officer, Philipp Spycher, Ph.D., will be a speaker at the Next Generation Protein Therapeutics Summit hosted by Informa Connect. The presentation will highlight Araris’ proprietary linker technology, ...
Pharmaceutical enterprises have been confronted with numerous challenges, such as rising cost pressures and uncertainty in the upstream supply of APIs, antibodies, enzymes, therapeutic proteins, etc. BOC Sciences, featured with a comprehensive fermentation platform, is able to lift them out of the plight by culturing diverse microbial strains (usually fungi and ...
AVR-RD-03, AVROBIO’s gene therapy for Pompe disease, includes a proprietary Glycosylation-Independent Lysosomal Targeting (GILT)-tag which consists of a short peptide sequence linked to the therapeutic protein and is designed to enhance uptake in targeted tissues. ...
ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases The companies agree a follow-on collaboration to evaluate ViGeneron’s adeno-associated virus vectors (vgAAVs) for delivering Daiichi Sankyo’s novel therapeutic protein to treat prevalent eye diseases ViGeneron GmbH, a ...
The publication, “Development of Spirulina for the Manufacture and Oral Delivery of Protein Therapeutics” is accessible online here. “Genetic engineering has transformed the manufacturing of biological products over the past 50 years, yet plant-based biopharmaceutical production has remained an elusive challenge,” said Jim Roberts, M.D., ...
(fka Corgentech, South San Francisco, CA), a developer of drugs for treating pain and inflammation, and Director, Corporate Development, at GeneTrol Biotherapeutics (Oakland, CA), a developer of therapeutic proteins for the treatment of cancer, viral infections and autoimmune diseases. ...
Aurealis Therapeutics, a synthetic biology company developing ground-breaking four-in-one cell and gene therapies, announced today the publication of the first study on its investigational product AUP-16, a four-in-one -combination therapy using live Lactococcus lactis expressing three human therapeutic proteins for the treatment of chronic ...
ACTM-838 is Actym's lead clinical development candidate for the treatment of solid tumors. The therapeutic candidate is based on the company's immunotherapy platform called STACT (S. ...
CADD techniques at Creative Biostructure Drug Discovery include but are not limited to: ADMET Modeling and Prediction Molecular Dynamic Simulation De Novo Design Pharmacophore Modeling Fragment-to-Lead Targeting Fishing Structure-based Virtual Screening Target Modeling Ligand-based Virtual Screening Quantum Mechanics Molecular Docking Quantitative Structure-Activity Relationship Modeling Some ...
Protease inhibitor is a key component of Oramed’s PODTM technology that protects therapeutic proteins in the digestive system Oramed has already been granted this patent in the United States and Japan Oramed Pharmaceuticals Inc. ...